Medicenna Therapeutics Corp.
NASDAQ:MDNA
Overview | Financials
Company Name | Medicenna Therapeutics Corp. |
Symbol | MDNA |
Currency | USD |
Price | 0.157 |
Market Cap | 0 |
Dividend Yield | 0% |
52-week-range | 0.151 - 0.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Fahar Merchant Ph.D. |
Website | https://www.medicenna.com |
An error occurred while fetching data.
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD